Cabaletta Bio Past Earnings Performance
Past criteria checks 0/6
Cabaletta Bio's earnings have been declining at an average annual rate of -26.7%, while the Biotechs industry saw earnings growing at 13.2% annually.
Key information
-26.7%
Earnings growth rate
43.0%
EPS growth rate
| Biotechs Industry Growth | 12.9% |
| Revenue growth rate | n/a |
| Return on equity | -45.1% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Cabaletta Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -90 | 24 | 77 |
| 31 Mar 24 | 0 | -77 | 21 | 65 |
| 31 Dec 23 | 0 | -68 | 19 | 55 |
| 30 Sep 23 | 0 | -62 | 17 | 50 |
| 30 Jun 23 | 0 | -57 | 16 | 45 |
| 31 Mar 23 | 0 | -56 | 16 | 43 |
| 31 Dec 22 | 0 | -53 | 15 | 39 |
| 30 Sep 22 | 0 | -51 | 15 | 37 |
| 30 Jun 22 | 0 | -51 | 15 | 37 |
| 31 Mar 22 | 0 | -50 | 14 | 35 |
| 31 Dec 21 | 0 | -46 | 14 | 32 |
| 30 Sep 21 | 0 | -42 | 14 | 28 |
| 30 Jun 21 | 0 | -39 | 13 | 26 |
| 31 Mar 21 | 0 | -36 | 13 | 23 |
| 31 Dec 20 | 0 | -33 | 13 | 21 |
| 30 Sep 20 | 0 | -29 | 12 | 18 |
| 30 Jun 20 | 0 | -26 | 11 | 16 |
| 31 Mar 20 | 0 | -21 | 9 | 13 |
| 31 Dec 19 | 0 | -22 | 7 | 11 |
| 30 Sep 19 | 0 | -19 | 5 | 10 |
| 30 Jun 19 | 0 | -23 | 4 | 9 |
| 31 Mar 19 | 0 | -21 | 3 | 7 |
| 31 Dec 18 | 0 | -12 | 2 | 4 |
Quality Earnings: CABA * is currently unprofitable.
Growing Profit Margin: CABA * is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CABA * is unprofitable, and losses have increased over the past 5 years at a rate of 26.7% per year.
Accelerating Growth: Unable to compare CABA *'s earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CABA * is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3%).
Return on Equity
High ROE: CABA * has a negative Return on Equity (-45.1%), as it is currently unprofitable.